StreetInsider.com News Articles

Piper Sandler on Biotechnology: 'Look for Biotech to Outperform through YE:26'

Tue, 01 Sep 2026 09:07:24 -0400

Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.

The analyst commented: "Look for Biotech to Outperform through YE:26 with Multiple Value Driving Events; Biotech had a strong summer exemplified by Moderna's (MRNA) 177% single day move on positive INTERpath-001 data. We expect Biotech to finish the year strong driven by commercial growth, validating clinical data, unprecedented innovation and continued M&A. We look for growth of Alnylam's (ALNY) AMVUTTRA, Legend's (LEGN) CARVYKTI and Mesoblast's (MESO) Ryoncil. Capricor (CAPR) has a November 22nd PDUFA date for deromicel in DMD, Moderna will present intismeran data, Arrowhead (ARWR) will file the sNDA for

Piper Sandler on Biotechnology: 'Look for Biotech to Outperform through YE:26'

Tue, 01 Sep 2026 09:07:24 -0400

Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.

Piper Sandler on Biotechnology: 'Look for Biotech to Outperform through YE:26'

Tue, 01 Sep 2026 09:07:24 -0400

Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.

Piper Sandler on Biotechnology: 'Look for Biotech to Outperform through YE:26'

Tue, 01 Sep 2026 09:07:24 -0400

Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.

Piper Sandler on Biotechnology: 'Look for Biotech to Outperform through YE:26'

Tue, 01 Sep 2026 09:07:24 -0400

Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.

Piper Sandler on Biotechnology: 'Look for Biotech to Outperform through YE:26'

Tue, 01 Sep 2026 09:07:24 -0400

Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.

Piper Sandler on Biotechnology: 'Look for Biotech to Outperform through YE:26'

Tue, 01 Sep 2026 09:07:24 -0400

Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.

Piper Sandler on Biotechnology: 'Look for Biotech to Outperform through YE:26'

Tue, 01 Sep 2026 09:07:24 -0400

Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.

Piper Sandler on Biotechnology: 'Look for Biotech to Outperform through YE:26'

Tue, 01 Sep 2026 09:07:24 -0400

Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.

Piper Sandler on Biotechnology: 'Look for Biotech to Outperform through YE:26'

Tue, 01 Sep 2026 09:07:24 -0400

Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.

Piper Sandler on Biotechnology: 'Look for Biotech to Outperform through YE:26'

Tue, 01 Sep 2026 09:07:24 -0400

Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.

Piper Sandler on Biotechnology: 'Look for Biotech to Outperform through YE:26'

Tue, 01 Sep 2026 09:07:24 -0400

Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.

Piper Sandler on Biotechnology: 'Look for Biotech to Outperform through YE:26'

Tue, 01 Sep 2026 09:07:24 -0400

Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.

Piper Sandler on Biotechnology: 'Look for Biotech to Outperform through YE:26'

Tue, 01 Sep 2026 09:07:24 -0400

Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.

Form SCHEDULE 13G/A SUTRO BIOPHARMA, INC. Filed by: PERCEPTIVE ADVISORS LLC

Fri, 14 Aug 2026 17:24:00 -0400

si-local-file:///var/storage/secattach/20260814/26932872.html

Form SCHEDULE 13G/A SUTRO BIOPHARMA, INC. Filed by: PERCEPTIVE ADVISORS LLC

Fri, 14 Aug 2026 17:24:00 -0400

si-local-file:///var/storage/secattach/20260814/26932872.html

Form SCHEDULE 13G/A SUTRO BIOPHARMA, INC. Filed by: Point72 Asset Management, L.P.

Fri, 14 Aug 2026 16:17:00 -0400

si-local-file:///var/storage/secattach/20260814/26930661.html

Form SCHEDULE 13G/A SUTRO BIOPHARMA, INC. Filed by: Point72 Asset Management, L.P.

Fri, 14 Aug 2026 16:17:00 -0400

si-local-file:///var/storage/secattach/20260814/26930661.html

Sutro Biopharma (STRO) PT Lowered to $34 at Citizens on Q2 Revenue Miss

Thu, 13 Aug 2026 04:13:00 -0400

Citizens analyst Reni Benjamin lowered the price target on Sutro Biopharma (NASDAQ: STRO) to $34.00 (from $41.00) while maintaining a Market Outperform rating.

The analyst commented, "For 2Q26, Sutro reported $9.8MM in revenue, lower than our estimate of $14.8MM (Figure 1). R&D expenses were $31.7MM, lower than our estimate of $39.6MM. SG&A expenses were $7.8MM, slightly higher than our estimate of $7.7MM. The company reported 2Q26 EPS of ($2.33) compared to our estimate of ($2.39) and ended the quarter with $164.3MM in cash."

Sutro Biopharma (STRO) PT Lowered to $34 at Citizens on Q2 Revenue Miss

Thu, 13 Aug 2026 04:13:00 -0400

Citizens analyst Reni Benjamin lowered the price target on Sutro Biopharma (NASDAQ: STRO) to $34.00 (from $41.00) while maintaining a Market Outperform rating.

Sutro Biopharma Inc. (STRO) Misses Q2 EPS by 13c

Wed, 12 Aug 2026 07:59:25 -0400

Sutro Biopharma Inc. (NASDAQ: STRO) reported Q2 EPS of ($2.33), $0.13 worse than the analyst estimate of ($2.20). Revenue for the quarter came in at $9.84 million versus the consensus estimate of $11.58 million.

For earnings history and earnings-related data on Sutro Biopharma Inc. (STRO) click here.

Form 10-Q SUTRO BIOPHARMA, INC. For: Jun 30

Wed, 12 Aug 2026 07:31:00 -0400

si-local-file:///var/storage/secattach/20260812/26908945.html

Form 10-Q SUTRO BIOPHARMA, INC. For: Jun 30

Wed, 12 Aug 2026 07:31:00 -0400

si-local-file:///var/storage/secattach/20260812/26908945.html

Form 8-K SUTRO BIOPHARMA, INC. For: Aug 12

Wed, 12 Aug 2026 07:19:00 -0400

si-local-file:///var/storage/secattach/20260812/26908875.html

Form 8-K SUTRO BIOPHARMA, INC. For: Aug 12

Wed, 12 Aug 2026 07:19:00 -0400

si-local-file:///var/storage/secattach/20260812/26908875.html